Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Preferred Stock Liabilities (2019 - 2022)

Korro Bio's Preferred Stock Liabilities history spans 3 years, with the latest figure at $12.5 million for Q4 2022.

  • For the quarter ending Q4 2022, Preferred Stock Liabilities fell 83.92% year-over-year to $12.5 million, compared with a TTM value of $12.5 million through Dec 2022, down 83.92%, and an annual FY2022 reading of $12.5 million, down 83.92% over the prior year.
  • Preferred Stock Liabilities for Q4 2022 was $12.5 million at Korro Bio, down from $77.7 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $147.9 million in Q3 2019, with the low at $12.5 million in Q4 2022.
  • Average Preferred Stock Liabilities over 3 years is $79.4 million, with a median of $77.7 million recorded in 2021.
  • Biggest YoY gain for Preferred Stock Liabilities was 83.92% in 2022; the steepest drop was 83.92% in 2022.
  • Tracing KRRO's Preferred Stock Liabilities over 3 years: stood at $147.9 million in 2019, then tumbled by 47.44% to $77.7 million in 2021, then crashed by 83.92% to $12.5 million in 2022.
  • Per Business Quant, the three most recent readings for KRRO's Preferred Stock Liabilities are $12.5 million (Q4 2022), $77.7 million (Q4 2021), and $147.9 million (Q3 2019).